In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Low renal function is associated with poor physical function and exercise capacity in patients with chronic cardiovascular disease

Session Poster session 4

Speaker Akihiro Aoyama

Event : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Poster Session

Authors : A Aoyama (Sagamihara,JP), M Yamaoka-Tojo (Sagamihara,JP), S Obara (sagamihara,JP), T Kutsuna (sagamihara,JP), K Fujiyoshi (Sagamihara,JP), E Sekine (sagamihara,JP), Y Takahashi (sagamihara,JP), C Noda (Sagamihara,JP), A Matsunaga (Sagamihara,JP), J Ako (Sagamihara,JP)

Authors:
A. Aoyama1 , M. Yamaoka-Tojo2 , S. Obara3 , T. Kutsuna3 , K. Fujiyoshi4 , E. Sekine3 , Y. Takahashi3 , C. Noda4 , A. Matsunaga2 , J. Ako4 , 1Kitasato University Graduate School of Medical Sciences - Sagamihara - Japan , 2Kitasato University, School of Allied Health Sciences, Department of Rehabilitation - Sagamihara - Japan , 3Kitasato University East Hospital, Department of Rehabilitation - Sagamihara - Japan , 4Kitasato University, School of Medicine, Department of Cardiovascular Medicine - Sagamihara - Japan ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 713

Background: Poor physical function and exercise capacity are strongly associated with an increased risk for cardiovascular events and mortality in patients with cardiovascular disease (CVD). Although several studies have reported that low renal function decreases physical function and exercise capacity in elderly people and patients with acute CVD or chronic kidney disease, few studies have addressed the relationship between renal function and physical function including exercise capacity in patients with chronic CVD.

Purpose: To examine the association between estimated glomerular filtration rate (eGFR) as a parameter of renal function and physical function in patients with chronic CVD.

Methods: We recruited 372 outpatients with chronic CVD with New York Heart Association functional classification class 1–2. We evaluated 356 patients after excluding those with eGFR (mL/min/1.73 m2) <30, hemodialytic patients, or those who needed assistance for walking. Blood hemoglobin, albumin, and brain natriuretic peptide (BNP) were measured and patient' characteristics including age, sex, body mass index (BMI), comorbidity, eGFR, and left ventricular ejection fraction (LVEF) were assessed. We also measured handgrip strength, quadriceps isometric strength (QIS), walking velocity, and one leg standing (OLS) time as parameters of physical function, and 6-min walk distance (6MWD) as a parameter of exercise capacity. The 356 patients were divided in three groups according to eGFR: 30–45; 45–60; and >60. We compared all parameters of physical function and exercise capacity among the three groups.

Results: The study population consisted of 356 patients with mean age of 72.0±8.4 years and 74.4% of males. With regard to cardiovascular diseases, 44.3% had angina pectoris, 44.6% had old myocardial infraction, and 42.9% had compensated heart failure. Lower eGFR values were associated with weaker handgrip strength and QIS, slower walking velocity, and shorter OLS time and 6MWD (p for trend <0.001). After adjusting for age, sex, BMI, comorbidity, haemoglobin, albumin, BNP, and LVEF, patients with eGFR 30–45 had shorter OLS time (adjusted mean: 21.9 s vs. 41.9 s; p<0.001) and 6MWD (adjusted mean: 454 m vs. 517 m; p<0.001), and slower walking velocity (adjusted mean: 1.4 m/s vs. 1.8 m/s; p<0.001) compared with those with eGFR >60. There were no significant differences in handgrip strength and QIS.

Conclusion: Low renal function was associated with poor physical function and exercise capacity in patients with chronic CVD.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are